Positions

Professor of Medicine and Surgery
Division of Abdominal Transplantation
Baylor College of Medicine
Chief of Hepatology
Baylor College of Medicine
Director, Baylor Liver Health
Baylor College of Medicine

Education

Residency from University of Rochester Strong Memorial Hospital
M.D. from Stanford University School Of Medicine
Gastroenterology Fellowship from University Of California, San Francisco School Of Medicine
Clinical Associate from National Institutes Of Health

Certifications

Diplomate - Transplant Hepatology
American Board of Internal Medicine
Diplomate - Gastroenterology
American Board of Internal Medicine
Diplomate - Internal Medicine
American Board of Internal Medicine
Diplomate
National Board of Medical Examiners

Honors & Awards

Distinguished Scientist Award
George Jamieson Award for Outstanding Public Service
Best Doctors in America
America’s Top Doctors
Who’s Who in America
America’s Registry of Outstanding Professionals
Who’s Who in Science and Engineering

Professional Interests

  • Transplant Hepatology
  • Pre- and post-liver transplantation care
  • Liver failure
  • Hepatitis
  • Cirrhosis
  • Primary sclerosing cholangitis
  • Drug-induced liver injury
  • Wilson disease
  • Hemochromatosis
  • Alpha-1-antitrypsin deficiency
  • Hepatocellular carcinoma (HCC) and cholangocarcinoma,
  • Gastroesophageal varices
  • Hepatic encephalopathy

Professional Statement

Dr. Vierling is board certified in internal medicine and gastroenterology and a Fellow of the American College of Physicians. He created a liver transplant program at the University of Colorado Health Sciences Center.

Dr. John M. Vierling directs Advanced Liver Therapies, a clinical research unit devoted to hepatobiliary diseases. He and his research staff are conducting phase 1-3 studies of diagnostics and therapies in chronic hepatitis B, chronic hepatitis C, primary biliary cirrhosis, non-alcoholic fatty liver disease, anti-fibrotic therapy to prevent cirrhosis, hepatic encephalopathy, and measurement of hepatocellular function using 13C-labeled compounds.

Dr. Vierling’s basic science laboratory investigations have used murine models to study the immunopathogenesis of non-suppurative destructive cholangitis, which destroys bile ducts in primary biliary cirrhosis, an autoimmune liver disease, as well as in two alloimmune diseases, hepatic allograft rejection and chronic graft-versus-host disease. Dr. Vierling is the author of numerous research publications.

Dr. Vierling’s primary research interests are the immunopathogenic mechanisms involved in hepatobiliary injury caused by viral infection, autoimmunity, alloimmunity, and non-alcoholic fatty liver disease. By emphasizing a "laboratory bench to bedside" philosophy, Dr. Vierling has also been active in the design and execution of clinical therapeutic trials of antiviral agents for treatment of hepatitis B and C infections in patients before and after liver transplantation, and trials of immunosuppressive drugs in liver transplantation and autoimmune liver diseases.

Selected Publications

Memberships

American Association for the Study of Liver Diseases
American Gastroenterological Association